SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Helium is a decentralized machine network powered by a physical blockchain. The network is created by gateways who also double as miners on our network. These gateway operators can earn tokens based on coverage they provide as well as transaction fees gained from machines connecting to their gateway  Helium is a new cryptocurrency. Hotspots earn for providing and validating wireless coverage and when devices on the network connect to the internet through Hospots  Helium is mined and distributed to Hotspot Owners, Helium Inc, and investors. There is no pre-mine of Helium, and every month approximately 5,000,000 new Helium are minted.  At the end of each mining period, roughly every 30 to 60 mins, Helium is distributed according to the allocation shown:

Helium

Heliums rally is being tied primarily to reported adoption by Celina, Texas, where the city is using the Helium networksupporting the broader DePIN and real-world wireless utility narrative. Bullish traders view the development as fuel for continued momentum and a possible short squeeze, while skeptics point to weak hotspot economics, dilution, and management concerns.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A BMF short report questioning the statistical power, control arm, and valuation of SELLASs REGAL Phase 3 AML trial drove attention and selling pressure. Traders remain divided: bears see meaningful downside risk if the trial fails, while bulls dismiss the report and focus on the pending 80th-event announcement and topline readout as potential catalysts.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

A quarterly earnings beat and raised full-year outlook, supported by Innovative Medicine growth, are reinforcing bullish sentiment as investors rotate into defensive healthcare. Traders remain divided over softer MedTech performance and patent-related pressure, but many view J&J as a resilient, cash-generating healthcare leader.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

U.S. tariffs on imported drones and components, alongside expectations for increased Pentagon spending, have focused attention on Red Cat as a domestic defense-drone supplier. Traders are split between bullish views that tariffs and prospective government contracts could benefit RCAT and skepticism centered on the lack of confirmed large orders, dilution, losses, and repeated management promises.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck and Modernas personalized mRNA cancer vaccine, used with Keytruda, met key Phase 3 recurrence and metastasis endpoints in resected melanoma, renewing enthusiasm for Mercks oncology pipeline and helping drive the shares to new highs. Traders remain divided over how much of the opportunity is already priced in, with pending full data, regulatory review, manufacturing complexity and Keytrudas eventual patent expiry cited as risks.

Vanguard Index Funds - Vanguard Morningstar Total Stock Market ETF

Vanguard Total Stock Market ETF

Broad-market diversification and long-term buy-and-hold investing are driving attention, with traders presenting VTI as a core alternative to concentrated tech exposure amid concerns over AI valuations, rising rates, debt, and geopolitical risk. The community is divided between investors accumulating VTI as a defensive retirement anchor and bears warning that its heavy mega-cap exposure could leave it vulnerable to a broader correction.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It operates through the following segments: Uranium, Rare Earth Elements (REE), and Heavy Mineral Sands (HMS). The uranium segment engages in conventional and ISR uranium extraction, recovery and sales of uranium from mineral properties and the recycling of uranium-bearing materials generated by third parties along with the exploration, permitting and evaluation of uranium properties in the U.S. The REE segment is engaged in the company’s initiatives to progress towards full REE separation capabilities at the Mill to produce both light and heavy separated REE oxides in the coming years. The HMS segment engages in the exploration, development and recovery of HMS at the Kwale Project, Bahia Project, Vara Mada Project and the company’s equity method investments in the Donald Project JV and Tate. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels is drawing attention around the reported completion of its Australian Strategic Materials acquisition, which traders view as adding rare-earth metals and alloy capacity and advancing the companys Western mine-to-magnet supply chain. The community remains divided between long-term optimism over rare-earth, uranium, and government-backed critical-minerals demand and frustration with the stocks weak price action and execution risk.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

Attention is centered on the Treasurys expanded long-term bond buyback plan and speculation that Treasury Secretary Bessent could use cash reserves to suppress long-end yields, prompting bullish short-squeeze hopes for TLT. The community is divided, with skeptics arguing the intervention is temporary and insufficient against persistent inflation, heavy government borrowing, oil pressures, and a potentially hawkish Fed.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Reports that Visa placed Hims & Hers in a monitoring program over elevated credit-card disputes tied to its weight-loss subscriptions, alongside ongoing FTC scrutiny, are driving attention. Traders are split between viewing the selloff as an overreaction to limited fees and fearing stricter payment or business-practice requirements could hurt customer confidence and margins.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

Higher Treasury yields and renewed Federal Reserve rate-hike fears are driving biotech lower, with traders highlighting the sectors sensitivity to discount rates and financing conditions. Some view the decline as a temporary pullback within a broader biotech rotation, while others warn that elevated rates could prolong weakness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates

Gyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of -50.00% and +10.94%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Cytokinetics (CYTK) Reports Q2 Loss, Beats Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of +7.98% and +40.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for May 27th

GYRE, FSUN and AKZOY have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2026.

Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates

Gyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of +16.67% and -33.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Gyre Therapeutics (NASDAQ:GYRE) Trading Up 2% - Should You Buy?

Gyre Therapeutics (NASDAQ:GYRE) Trading 2% Higher - Here's What Happened...

Gyre Therapeutics (GYRE) to Release Earnings on Tuesday

Gyre Therapeutics (NASDAQ:GYRE) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 31. (View Earnings Report at...

Zacks Research Downgrades Gyre Therapeutics (NASDAQ:GYRE) to Strong Sell

Zacks Research lowered shares of Gyre Therapeutics from a "hold" rating to a "strong sell" rating in a report on Monday...

Gyre Therapeutics (NASDAQ:GYRE) Trading Down 8.2% - Time to Sell?

Gyre Therapeutics (NASDAQ:GYRE) Trading Down 8.2% - Should You Sell...

Gyre Therapeutics (NASDAQ:GYRE) Announces Earnings Results

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) posted its earnings results on Thursday. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.04). The...

Gyre Therapeutics (NASDAQ:GYRE) Downgraded by Wall Street Zen to Hold

Wall Street Zen cut Gyre Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday...

• Reported GAAP EPS of -$0.12
• Reported revenue of $29.11M up 8.72% YoY
• Gyre Therapeutics, Inc. affirmed its full year 2026 revenue guidance of $100.5 million to $111.0 million, reflecting the company's outlook for its commercial-stage biopharmaceutical product portfolio and development initiatives.

Gyre Therapeutics, Inc. experienced a wider net loss, a year-over-year decrease in quarterly revenues, and an 11% reduction in total cash position compared to the end of the prior year.

Gyre Therapeutics, Inc. expanded its pipeline through the strategic acquisition of Cullgen and achieved regulatory progress with F351 while driving higher sales volumes for its primary product, ETUARY.

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The firm operates two distinct segments: Gyre Pharmaceuticals and Gyre. The Gyre Pharmaceuticals segment extends three major commercial drug products including ETUARY, Etorel, and Contiva as well as several product candidates in preclinical and clinical development. The Gyre segment consists of the development and commercialization of Hydronidone for the treatment of metabolic dysfunction-associated steatohepatitis associated liver fibrosis. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.

Gyre Therapeutics Inc

Pulmatrix Shares Dive As Privately-Held Pharma Company Chooses To Merge With Gyre Therapeutics Instead

Equity

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a positive week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

GYRE Gyre Therapeutics Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest GYRE News